RhumbLine Advisers
LBRX

RhumbLine Advisers’s LB Pharmaceuticals LBRX Stock Holding History

RhumbLine Advisers’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$422K Buy
17,103
+820
+5% +$18.9K ﹤0.01% 2715
2025
Q4 		$362K Buy
+16,283
New +$284K ﹤0.01% 2865

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

RhumbLine Advisers's LBRX Position: Q1 2026 in Review

RhumbLine Advisers increased its LB Pharmaceuticals (LBRX) stake by 5% in Q1 2026, buying an estimated $18.9K and bringing the position to 17,103 shares worth $422K. The position accounts for ﹤0.01% of the portfolio, ranked #2715.

RhumbLine Advisers first reported a position in LBRX in Q4 2025 and has held it in 2 quarters since. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

  • RhumbLine Advisers held 17,103 shares of LB Pharmaceuticals worth $422K as of Q1 2026.
  • RhumbLine Advisers bought 820 LB Pharmaceuticals shares in Q1 2026, an estimated $18.9K.
  • LB Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2715 holding.
  • RhumbLine Advisers first reported a position in LB Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.